DRIO stock gains 11% on benefits of diabetes solution (NASDAQ:DRIO)
seekingalpha.com
science
2022-06-03 18:04:59

RapidEye/E+ via Getty Images DarioHealth (NASDAQ:DRIO), a digital therapeutics company focused on chronic conditions, added over 11% on Friday in reaction to results from three new studies highlighting the benefits of its integrated solution to diabetic patients. The first study designed to examine patients with diabetes as well as hypertension indicated 'significant improvements' for both conditions after six months, the company said, noting that ~39% of patients lowered their hypertension by one stage.
